KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) EPS (Basic) (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed EPS (Basic) for 15 consecutive years, with -$0.25 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Basic) rose 64.79% year-over-year to -$0.25, compared with a TTM value of -$0.57 through Dec 2025, up 86.03%, and an annual FY2025 reading of -$0.57, up 86.03% over the prior year.
  • EPS (Basic) was -$0.25 for Q4 2025 at Travere Therapeutics, down from $0.29 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $1.97 in Q3 2023 and bottomed at -$1.76 in Q1 2024.
  • Average EPS (Basic) over 5 years is -$0.72, with a median of -$0.94 recorded in 2021.
  • The sharpest move saw EPS (Basic) tumbled 4900.0% in 2021, then soared 280.73% in 2023.
  • Year by year, EPS (Basic) stood at -$1.46 in 2021, then increased by 29.45% to -$1.03 in 2022, then dropped by 12.62% to -$1.16 in 2023, then surged by 38.79% to -$0.71 in 2024, then soared by 64.79% to -$0.25 in 2025.
  • Business Quant data shows EPS (Basic) for TVTX at -$0.25 in Q4 2025, $0.29 in Q3 2025, and -$0.14 in Q2 2025.